2014 CME Symposia - Dinner Symposium B
Register for the CMHC today to sign up for these value-added CME/CE activities-at no additional cost!
Pre-registration for symposia will open at the end of August for CMHC registrants to make selections. There are no additional fees to attend. Symposia include meals or refreshments and seating is limited and on a first-come, first-serve basis.
Dinner Symposium B
Thursday · 7:00 - 9:00pm
Novel and Emerging Combinations to Achieve Glycemic Control and Reduce
A Focus on Incretin-Based Therapy and SGLT2 Inhibitors
Supported by an educational grant from AstraZeneca
Newer treatment options, including sodium glucose co-transporter-2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, and several fixed-dose combinations are available or are under development, and may change the treatment paradigm for T2DM. These evidence-based therapies have the potential to work synergistically in combination with other available interventions to achieve glycemic control and to reduce overall cardiometabolic risk for individuals with T2DM. This symposium will keep clinicians apprised of new clinical trial data and developments and discuss how to appropriately integrate these newer and emerging therapies into clinical practice.
- Assess the benefits and limitations of currently available antihyperglycemic therapies as well as the most common reasons patients with T2DM fail to achieve target HbA1c goals.
- Review the mechanisms of action of incretin-based therapy and SGLT2 inhibitors, and discuss the therapeutic advantages of targeting their novel pathways.
- Provide healthcare providers with current guideline recommendations concerning how to appropriately integrate combination therapies into clinical practice.
- Analyze the clinical trial data on these new classes of drugs, such as dual or triple combination therapy, in patients with T2DM at various stages of the disease.
- Help clinicians understand how to improve outcomes in patients with diabetes by selecting appropriate and effective therapies that tighten glycemic control and reduce overall cardiometabolic risk in patients with T2DM.
Preliminary Agenda & Faculty
|7:00 - 7:15pm
||Chairperson: George L. Bakris, MD
|7:15 - 7:40pm
||The Role of Incretin Therapies and Effects on Metabolic Homeostasis
||Presenter: Richard E. Pratley, MD
|7:40 - 8:05pm
||Renal Involvement in the Control of Plasma Glucose
||Presenter: Mark E. Molitch, MD
|8:05 - 8:30pm
||Current and Novel Approaches to Glycemia Management: A Focus on Combination Therapy
||Presenter: Sunder Mudaliar, MD
|8:30 - 9:00pm
||Exploring Synergistic Approaches to Improve Glucose Control and CV Risk Factors:
Interactive, Case-Based Scenarios, Panel Discussion and Debate along with Audience Q&A
|Moderator: George L. Bakris, MD
Presenters & discussants: Mark E. Molitch, MD; Sunder Mudaliar, MD; Richard E. Pratley, MD
Mark E. Molitch, MD
- Martha Leland Sherwin Professor of Endocrinology
- Div. of Endocrinology, Metabolism and Molecular Medicine
- Northwestern Univ. Feinberg School of Medicine
Sunder Mudaliar, MD
Staff Physician and Director Diabetes Clinic
VA San Diego Healthcare System
Clinical Professor of Medicine
University of California, San Diego
San Diego, CA
Richard E. Pratley, MD
Samuel E. Crockett Chair in Diabetes Research
Medical Director, AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead, AdventHealth Translational Research Institute; Adjunct Professor of Medicine, Johns Hopkins University School of Medicine
George L. Bakris, MD
Professor of Medicine
Director, ASH Comprehensive Hypertension Center
University of Chicago Medicine
View Complete Accreditation Details and Program Overview: CMHC Accreditation